MEDucated

Menu

Search

Evidence-grounded comparison · non-production preview

Compare supplement evidence clearly.

Review two canonical supplement records topic by topic, with evidence availability, source boundaries, and limitations kept explicit—without rankings or recommendations.

What this comparison can establish

This comparison organizes two separately sourced supplement records. It describes evidence structure and availability without ranking supplements or recommending use.

Reference counts are descriptive. More references do not necessarily mean better or stronger evidence.

Identity boundaries

Selected supplement concepts

Supplement concepts, ingredients, and forms remain separate. Relationship differences do not establish clinical meaning.

mineral

Magnesium

Canonical supplement identity
ODS source attached

Modeled ingredients

  • Magnesiumingredient

Modeled forms

  • Magnesium glycinatemineral compound
  • Magnesium citratemineral compound
  • Magnesium oxidemineral compound

vitamin

Vitamin D

Also known as Calciferol
ODS source attached

Modeled ingredients

  • Ergocalciferolingredient
  • Cholecalciferolingredient

Modeled forms

  • Vitamin D2vitamin form
  • Vitamin D3vitamin form

Source boundaries

Selected ODS revisions

Each supplement retains its own immutable source revision, fingerprint, official URL, and medical-review state.
Selected NIH ODS revision

Magnesium

Magnesium — Fact Sheet for Health Professionals

Source ID
source:nih-ods:magnesium-health-professional
Source revision ID
source-revision:nih-ods:magnesium-health-professional:2026-08-10.0f8470209257
ODS revision date
January 6, 2026
Medical review
not medically reviewed
Source fingerprint
0f84702092574ff8a3b3fe01ab3a977c6a76d37e18b758e3e94b6d3ca55c3d59
Retrieved
2026-08-10T22:07:04.128Z
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Selected NIH ODS revision

Vitamin D

Vitamin D — Fact Sheet for Health Professionals

Source ID
source:nih-ods:vitamin-d-health-professional
Source revision ID
source-revision:nih-ods:vitamin-d-health-professional:2026-08-10.825b1a553a4a
ODS revision date
June 27, 2025
Medical review
not medically reviewed
Source fingerprint
825b1a553a4a177e2d87fc412b0b4b21daa72ca92f4334a0096bc0dfa7f70a3c
Retrieved
2026-08-10T22:07:04.753Z
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Structural orientation

What differs in these records

These statements describe record structure only and do not assign medical importance.

27 structural observations are available. Topic states remain visible in the aligned comparison below.

Inspect all structural observations
  • The selected ODS revision dates differ: January 6, 2026 for Magnesium and June 27, 2025 for Vitamin D.
  • Magnesium and Vitamin D have different modeled ingredient relationships. This is an identity distinction, not a clinical ranking.
  • Magnesium and Vitamin D have different modeled form relationships. No clinical interpretation is assigned to that difference.
  • The selected source blocks for “What it is” link 6 references for Magnesium and 4 references for Vitamin D.
  • The evidence profiles identify different reference types for “What it is”.
  • Source-backed evidence for “Common reasons people use it” is unavailable for both selected supplements.
  • Source-backed evidence for “What evidence has studied” is unavailable for both selected supplements.
  • Source-backed evidence for “Potential benefits studied” is unavailable for both selected supplements.
  • The selected source blocks for “Known risks and safety considerations” link 7 references for Magnesium and 10 references for Vitamin D.
  • The evidence profiles identify different reference types for “Known risks and safety considerations”.
  • Source-backed evidence for “Side effects” is unavailable for both selected supplements.
  • The selected source blocks for “Medication interaction evidence” link 5 references for Magnesium and 13 references for Vitamin D.
  • The evidence profiles identify different reference types for “Medication interaction evidence”.
  • Source-backed evidence for “Supplement interaction evidence” is unavailable for both selected supplements.
  • Source-backed evidence for “Food and nutrient interactions” is unavailable for both selected supplements.
  • The selected source blocks for “Typical forms” link 8 references for Magnesium and 10 references for Vitamin D.
  • The evidence profiles identify different reference types for “Typical forms”.
  • The selected source blocks contain different source-described limitation tags for “Typical forms”.
  • The selected source blocks for “Evidence-backed dosage information” link 1 reference for Magnesium and 6 references for Vitamin D.
  • The evidence profiles identify different reference types for “Evidence-backed dosage information”.
  • The selected source blocks for “Populations needing caution” link 9 references for Magnesium and 16 references for Vitamin D.
  • The evidence profiles identify different reference types for “Populations needing caution”.
  • Source-backed evidence for “Pregnancy and lactation considerations” is unavailable for both selected supplements.
  • The selected source blocks for “Laboratory and test considerations” link 4 references for Magnesium and 13 references for Vitamin D.
  • The evidence profiles identify different reference types for “Laboratory and test considerations”.
  • Source-backed evidence for “Regulatory information” is unavailable for both selected supplements.
  • Source-backed evidence for “Evidence limitations” is unavailable for both selected supplements.

Topic-by-topic evidence

Compare evidence availability and provenance

Each source block, reference, evidence profile, and inspector remains attached to its own supplement and ODS revision.

Evidence topic

What it is

Available for both

Magnesium

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
6 identified
Human evidence
Human evidence not identified in the frozen metadata
Randomized trials
Randomized trials not identified in the frozen metadata
Reviews and meta-analyses
Systematic reviews or meta-analyses not identified in the frozen metadata
Evidence recency
1997–2012
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Government reference1
  • Study type could not be determined5
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Institute of Medicine (IOM). Food and Nutrition Board. Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington, DC: National Academy Press, 1997.

    Government reference · Population basis: unknown · Directness: not assessed
  2. Rude RK. Magnesium. In: Coates PM, Betz JM, Blackman MR, Cragg GM, Levine M, Moss J, White JD, eds. Encyclopedia of Dietary Supplements. 2nd ed. New York, NY: Informa Healthcare; 2010:527-37.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  3. Rude RK. Magnesium. In: Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR, eds. Modern Nutrition in Health and Disease. 11th ed. Baltimore, Mass: Lippincott Williams & Wilkins; 2012:159-75.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  4. Volpe SL. Magnesium. In: Erdman JW, Macdonald IA, Zeisel SH, eds. Present Knowledge in Nutrition. 10th ed. Ames, Iowa; John Wiley & Sons, 2012:459-74.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  5. Elin RJ. Assessment of magnesium status for diagnosis and therapy. Magnes Res 2010;23:1-5. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  6. Gibson, RS. Principles of Nutritional Assessment, 2nd ed. New York, NY: Oxford University Press, 2005.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
Read imported source wording for Magnesium

Magnesium, an abundant mineral in the body, is naturally present in many foods, added to other food products, available as a dietary supplement, and present in some medicines (e.g., antacids, laxatives). Magnesium is a cofactor in more than 300 enzyme systems that regulate diverse biochemical reactions in the body, including protein synthesis, muscle and nerve function, blood glucose control, and blood pressure regulation [1-3]. Magnesium is required for energy production, oxidative phosphorylation, and glycolysis. It contributes to the structural development of bone and is required for the synthesis of DNA, RNA, and the antioxidant glutathione. Magnesium also plays a role in the active transport of calcium and potassium ions across cell membranes, a process that is important to nerve impulse conduction, muscle contraction, and normal heart rhythm [3].

An adult body contains approximately 25 grams magnesium, with 50% to 60% present in the bones and most of the rest in soft tissues [4]. Less than 1% of total magnesium is in blood serum, and these levels are kept under tight control. Normal serum magnesium concentrations range between 0.75 and 0.95 millimoles/liter(mmol/L) [1,5]. Hypomagnesemia is defined as a serum magnesium level less than 0.75 mmol/L [6]. Magnesium homeostasis is largely controlled by the kidneys, which typically excrete about 120 milligrams (mg) magnesium into the urine each day [2]. Urinary excretion is reduced when magnesium status is low [1].

Where did MEDucated get this?

Magnesium — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Introduction
ODS revision
January 6, 2026
Retrieved
2026-08-10T22:07:04.128Z
Source fingerprint
0f84702092574ff8a3b3fe01ab3a977c6a76d37e18b758e3e94b6d3ca55c3d59
Cited reference numbers
1, 2, 3, 4, 5, 6
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Vitamin D

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
4 identified
Human evidence
Human evidence not identified in the frozen metadata
Randomized trials
Randomized trials not identified in the frozen metadata
Reviews and meta-analyses
Systematic review or meta-analysis identified
Evidence recency
2010–2018
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Government reference1
  • Study type could not be determined2
  • Systematic review1
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.

    Government reference · Population basis: unknown · Directness: not assessed
  2. Norman AW, Henry HH. Vitamin D. In: Erdman JW, Macdonald IA, Zeisel SH, eds. Present Knowledge in Nutrition, 10th ed. Washington DC: Wiley-Blackwell, 2012.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  3. Jones G. Vitamin D. In: Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR, eds. Modern Nutrition in Health and Disease, 11th ed. Philadelphia: Lippincott Williams & Wilkins, 2014.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  4. Silva MC, Furlanetto TW. Intestinal absorption of vitamin D: A systematic review. Nutr Rev 2018;76:60-76. [PubMed abstract]

    Systematic review · Population basis: unknown · Directness: not assessed
Read imported source wording for Vitamin D

Vitamin D (also referred to as calciferol) is a fat-soluble vitamin that is naturally present in a few foods, added to others, and available as a dietary supplement. It is also produced endogenously when ultraviolet (UV) rays from sunlight strike the skin and trigger vitamin D synthesis.

Vitamin D obtained from sun exposure, foods, and supplements is biologically inert and must undergo two hydroxylations in the body for activation. The first hydroxylation, which occurs in the liver, converts vitamin D to 25-hydroxyvitamin D [25(OH)D], also known as calcidiol. The second hydroxylation occurs primarily in the kidney and forms the physiologically active 1,25-dihydroxyvitamin D [1,25(OH)2D], also known as calcitriol [1].

Vitamin D promotes calcium absorption in the gut and maintains adequate serum calcium and phosphate concentrations to enable normal bone mineralization and to prevent hypocalcemic tetany (involuntary contraction of muscles, leading to cramps and spasms). It is also needed for bone growth and bone remodeling by osteoblasts and osteoclasts [1-3]. Without sufficient vitamin D, bones can become thin, brittle, or misshapen. Vitamin D sufficiency prevents rickets in children and osteomalacia in adults. Together with calcium, vitamin D also helps protect older adults from osteoporosis.

Vitamin D has other roles in the body, including reduction of inflammation as well as modulation of such processes as cell growth, neuromuscular and immune function, and glucose metabolism [1-3]. Many genes encoding proteins that regulate cell proliferation, differentiation, and apoptosis are modulated in part by vitamin D. Many tissues have vitamin D receptors, and some convert 25(OH)D to 1,25(OH)2D.

In foods and dietary supplements, vitamin D has two main forms, D2 (ergocalciferol) and D3 (cholecalciferol), that differ chemically only in their side-chain structures. Both forms are well absorbed in the small intestine. Absorption occurs by simple passive diffusion and by a mechanism that involves intestinal membrane carrier proteins [4]. The concurrent presence of fat in the gut enhances vitamin D absorption, but some vitamin D is absorbed even without dietary fat. Neither aging nor obesity alters vitamin D absorption from the gut [4].

Where did MEDucated get this?

Vitamin D — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Introduction
ODS revision
June 27, 2025
Retrieved
2026-08-10T22:07:04.753Z
Source fingerprint
825b1a553a4a177e2d87fc412b0b4b21daa72ca92f4334a0096bc0dfa7f70a3c
Cited reference numbers
1, 2, 3, 4
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Evidence topic

Common reasons people use it

Unavailable for both

Magnesium

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Vitamin D

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Evidence topic

What evidence has studied

Unavailable for both

Magnesium

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Vitamin D

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Evidence topic

Potential benefits studied

Unavailable for both

Magnesium

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Vitamin D

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Evidence topic

Known risks and safety considerations

Available for both

Magnesium

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
7 identified
Human evidence
Human evidence identified
Randomized trials
Randomized trials not identified in the frozen metadata
Reviews and meta-analyses
Systematic reviews or meta-analyses not identified in the frozen metadata
Evidence recency
1997–2013
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Government reference1
  • Pharmacokinetic study1
  • Study type could not be determined5
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Institute of Medicine (IOM). Food and Nutrition Board. Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington, DC: National Academy Press, 1997.

    Government reference · Population basis: unknown · Directness: not assessed
  2. Ranade VV, Somberg JC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther 2001;8:345-57. [PubMed abstract]

    Pharmacokinetic study · Population basis: human · Directness: not assessed
  3. Musso CG Magnesium metabolism in health and disease. Int Urol Nephrol 2009;41:357-62. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  4. Natural Medicines Comprehensive Database. Magnesium. 2013.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  5. Kutsal E, Aydemir C, Eldes N, Demirel F, Polat R, Taspnar O, Kulah E. Severe hypermagnesemia as a result of excessive cathartic ingestion in a child without renal failure. Pediatr Emerg Care 2007;23:570-2. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  6. McGuire JK, Kulkarni MS, Baden HP. Fatal hypermagnesemia in a child treated with megavitamin/megamineral therapy. Pediatrics 2000;105:E18. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  7. Onishi S, Yoshino S. Cathartic-induced fatal hypermagnesemia in the elderly. Intern Med 2006;45:207-10. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
Source safety wording remains visible

Although the risk of acquiring too much magnesium from food is low among healthy people, high doses of magnesium from dietary supplements or medications can cause diarrhea, nausea, and abdominal cramping. Very high doses of magnesium can lead to magnesium toxicity, which can cause hypotension, vomiting, difficulty breathing, irregular heartbeat, cardiac arrest, and other signs and symptoms. A few cases of fatal hypermagnesemia have been reported. The Tolerable Upper Intake Level for supplemental magnesium is 350 mg for adults, and it ranges from 65 to 350 mg for children and adolescents, depending on age.

UL reference intakeSource intake rangeSource-described amount

Too much magnesium from food does not pose a health risk in healthy individuals because the kidneys eliminate excess amounts in the urine [29]. However, high doses of magnesium from dietary supplements or medications often result in diarrhea that can be accompanied by nausea and abdominal cramping [1]. The forms of magnesium that are most commonly reported to cause diarrhea include magnesium carbonate, chloride, gluconate, and oxide [12]. The diarrhea and laxative effects of magnesium salts are due to the osmotic activity of unabsorbed salts in the intestine and colon and the stimulation of gastric motility [57].

Very large doses of magnesium-containing laxatives and antacids (typically those that provide >5,000 mg/day magnesium) have been associated with magnesium toxicity [58], including fatal hypermagnesemia in a 28-month-old boy [59] and an elderly man [60]. Signs and symptoms of magnesium toxicity, which usually develop after serum concentrations exceed 1.74 to 2.61 mmol/L, can include hypotension, nausea, vomiting, facial flushing, retention of urine, ileus, depression, and lethargy before progressing to muscle weakness, difficulty breathing, extreme hypotension, irregular heartbeat, and cardiac arrest [29]. The risk of magnesium toxicity increases with impaired renal function or kidney failure because the ability to remove excess magnesium is reduced or lost [1,29].

Source-described amount

The FNB has established ULs for supplemental magnesium for healthy infants, children, and adults (see Table 3) [1]. For many age groups, the UL appears to be lower than the RDA. This occurs because the RDAs include magnesium from all sources—food, beverages, dietary supplements, and medications. The ULs only include magnesium from dietary supplements and medications; they do not include magnesium found naturally in food and beverages.

RDA reference intakeUL reference intake
Table 3: Tolerable Upper Intake Levels (ULs) for Supplemental Magnesium in Milligrams (mg) [1]
AgeMaleFemalePregnantLactating
0–6 monthsNone establishedNone established
7–12 monthsNone establishedNone established
1–3 years65 mg65 mg
4–8 years110 mg110 mg
9–13 years350 mg350 mg
14–18 years350 mg350 mg350 mg350 mg
19–30 years350 mg350 mg350 mg350 mg
31–50 years350 mg350 mg350 mg350 mg
51+ years350 mg350 mg
UL reference intakeSource-described amount
Where did MEDucated get this?

Magnesium — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Health Risks from Excessive Magnesium
ODS revision
January 6, 2026
Retrieved
2026-08-10T22:07:04.128Z
Source fingerprint
0f84702092574ff8a3b3fe01ab3a977c6a76d37e18b758e3e94b6d3ca55c3d59
Cited reference numbers
1, 12, 29, 57, 58, 59, 60
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Vitamin D

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
10 identified
Human evidence
Human evidence identified
Randomized trials
Randomized trial identified
Reviews and meta-analyses
Systematic review or meta-analysis identified
Evidence recency
2006–2019
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Government reference1
  • Study type could not be determined5
  • Case report2
  • Randomized controlled trial1
  • Meta-analysis1
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.

    Government reference · Population basis: unknown · Directness: not assessed
  2. Galior K, Grebe S, Singh R. Development of vitamin D toxicity from overcorrection of vitamin D deficiency: A review of case reports. Nutrients 2018, 10, 953. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  3. Auguste BL, Avila-Casado C, Bargman JM. Use of vitamin D drops leading to kidney failure in a 54-year-old man. CMAJ 2019;191:E390-4. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  4. Vogiatzi MG, Jacobson-Dickman E, DeBoer MD. Vitamin D supplementation and risk of toxicity in pediatrics: A review of current literature. J Clin Endocrinol Metab 2014;99:1132-41. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  5. Singh P, Trivedi N. Tanning beds and hypervitaminosis D: A case report. Ann Intern Med 2014;160:810-1. [PubMed abstract]

    Case report · Population basis: unknown · Directness: not assessed
  6. Laurent MR, Gielen E, Pauwels S, Vanderschueren D, Bouillon R. Hypervitaminosis D associated with tanning bed use: A case report. Ann Intern Med 2017;166:155-6. [PubMed abstract]

    Case report · Population basis: unknown · Directness: not assessed
  7. Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, Duenas A. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007;99:903-5. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  8. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-82. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  9. Malihi Z, Lawes CMM, Wu Z, Huang Y, Waayer D, Toop L, et al. Monthly high-dose vitamin D supplementation does not increase kidney stone risk or serum calcium: Results from a randomized controlled trial. Am J Clin Nutr 2019;109:1578-87. [PubMed abstract]

    Randomized controlled trial · Population basis: unknown · Directness: not assessed
  10. Malihi Z, Wu Z, Stewart AW, Lawes CMM, Scragg R. Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: A systematic review and meta-analysis. Am J Clin Nutr 2016;104:1039-51. [PubMed abstract]

    Meta-analysis · Population basis: unknown · Directness: not assessed
Source safety wording remains visible

Vitamin D toxicity can cause hypercalcemia, hypercalciuria, and high serum 25(OH)D concentrations; in extreme cases, it may lead to renal failure, calcification of soft tissues, cardiac arrhythmias, and death. Vitamin D toxicity is almost always a result of excessive intakes of vitamin D through supplements. Taking calcium supplements in combination with vitamin D supplements may increase the risk of certain adverse effects. The Tolerable Upper Intake Level for vitamin D ranges from 25 to 100 mcg (1,000–4,000 IU), depending on age.

UL reference intakeSource intake rangeSource-described amount

Excess amounts of vitamin D are toxic. Because vitamin D increases calcium absorption in the gastrointestinal tract, vitamin D toxicity results in marked hypercalcemia (total calcium greater than 11.1 mg/dL, beyond the normal range of 8.4–10.2 mg/dL), hypercalciuria, and high serum 25(OH)D levels (typically >375 nmol/l [150 ng/mL]) [158]. Hypercalcemia, in turn, can lead to nausea, vomiting, muscle weakness, neuropsychiatric disturbances, pain, loss of appetite, dehydration, polyuria, excessive thirst, and kidney stones.

Source intake rangeSource-described amount

In extreme cases, vitamin D toxicity causes renal failure, calcification of soft tissues throughout the body (including in coronary vessels and heart valves), cardiac arrhythmias, and even death. Vitamin D toxicity has been caused by consumption of dietary supplements that contained excessive vitamin D amounts because of manufacturing errors, that were taken inappropriately or in excessive amounts, or that were incorrectly prescribed by physicians, [158-160].

Experts do not believe that excessive sun exposure results in vitamin D toxicity because thermal activation of previtamin D3 in the skin gives rise to various non-vitamin D forms that limit formation of vitamin D3. Some vitamin D3 is also converted to nonactive forms [1]. However, frequent use of tanning beds, which provide artificial UV radiation, can lead to 25(OH)D levels well above 375 to 500 nmol/L (150–200 ng/mL) [161-163].

The combination of high intakes of calcium (about 2,100 mg/day from food and supplements) with moderate amounts of vitamin D (about 19 mcg [765 IU]/day from food and supplements) increased the risk of kidney stones by 17% over 7 years among 36,282 postmenopausal women who were randomly assigned to take 1,000 mg/day calcium and 10 mcg (400 IU)/day vitamin D or a placebo [164]. However, other, shorter (from 24 weeks to 5 years) clinical trials of vitamin D supplementation alone or with calcium in adults found greater risks of hypercalcemia and hypercalciuria, but not of kidney stones [165,166].

Source-described amount

The FNB established ULs for vitamin D in 2010 (Table 4) [1]. While acknowledging that signs and symptoms of toxicity are unlikely at daily intakes below 250 mcg (10,000 IU), the FNB noted that even vitamin D intakes lower than the ULs might have adverse health effects over time. The FNB recommended avoiding serum 25(OH)D levels above approximately 125 to 150 nmol/L (50–60 ng/mL), and it found that even lower serum levels (approximately 75–120 nmol/L [30–48 ng/mL]) are associated with increases in rates of all-cause mortality, risk of cancer at some sites (e.g., pancreas), risk of cardiovascular events, and number of falls and fractures among older adults.

Source-described amount
Table 4: Tolerable Upper Intake Levels (ULs) for Vitamin D in Micrograms (mcg) and International Units (IU) [1]
AgeMaleFemalePregnancyLactation
0–6 months25 mcg (1,000 IU)25 mcg (1,000 IU)
7–12 months38 mcg (1,500 IU)38 mcg (1,500 IU)
1–3 years63 mcg (2,500 IU)63 mcg (2,500 IU)
4–8 years75 mcg (3,000 IU)75 mcg (3,000 IU)
9–13 years100 mcg (4,000 IU)100 mcg (4,000 IU)
14–18 years100 mcg (4,000 IU)100 mcg (4,000 IU)100 mcg (4,000 IU)100 mcg (4,000 IU)
19–50 years100 mcg (4,000 IU)100 mcg (4,000 IU)100 mcg (4,000 IU)100 mcg (4,000 IU)
51–70 years100 mcg (4,000 IU)100 mcg (4,000 IU)
>70 years100 mcg (4,000 IU)100 mcg (4,000 IU)
UL reference intakeSource-described amount
Where did MEDucated get this?

Vitamin D — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Health Risks from Excessive Vitamin D
ODS revision
June 27, 2025
Retrieved
2026-08-10T22:07:04.753Z
Source fingerprint
825b1a553a4a177e2d87fc412b0b4b21daa72ca92f4334a0096bc0dfa7f70a3c
Cited reference numbers
158, 159, 160, 1, 161, 162, 163, 164, 165, 166
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Evidence topic

Side effects

Unavailable for both

Magnesium

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Vitamin D

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Evidence topic

Medication interaction evidence

Available for both

Magnesium

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
5 identified
Human evidence
Human evidence not identified in the frozen metadata
Randomized trials
Randomized trials not identified in the frozen metadata
Reviews and meta-analyses
Systematic reviews or meta-analyses not identified in the frozen metadata
Evidence recency
2001–2013
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Study type could not be determined4
  • Regulatory source1
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Natural Medicines Comprehensive Database. Magnesium. 2013.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  2. Dunn CJ, Goa KL. Risedronate: A review of its pharmacological properties and clinical use in resorptive bone disease. Drugs 2001;61:685-712. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  3. Arayne MS, Sultana N, Hussain F. Interactions between ciprofloxacin and antacids--dissolution and adsorption studies. Drug Metabol Drug Interact 2005;21:117-29. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  4. Sarafidis PA, Georgianos PI, Lasaridis AN. Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy. Expert Opin Drug Saf 2010;9:259-73. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  5. U.S. Food and Drug Administration. Proton Pump Inhibitor Drugs (PPIs): Drug Safety Communication—Low Magnesium Levels Can Be Associated With Long-Term Use. March 2, 2011.

    Regulatory source · Population basis: unknown · Directness: not assessed
Source safety wording remains visible

Magnesium may interact with certain medications, such as oral bisphosphonates, tetracyclines, and quinolone antibiotics. In addition, some medications, including diuretics and proton pump inhibitors, can affect magnesium status.

Several types of medications have the potential to interact with magnesium supplements or affect magnesium status. A few examples are provided below. People who are taking these and other medications on a regular basis should discuss their magnesium intakes with their health care providers.

Magnesium-rich supplements or medications can decrease the absorption of oral bisphosphonates, such as alendronate (Fosamax), that are used to treat osteoporosis [61]. Taking magnesium-rich supplements or medications at least 2 hours before or after oral bisphosphonates can minimize this interaction [57].

Magnesium can form insoluble complexes with tetracyclines, such as demeclocycline (Declomycin) and doxycycline (Vibramycin), and with quinolone antibiotics, such as ciprofloxacin (Cipro) and levofloxacin (Levaquin). These antibiotics should be taken at least 2 hours before or 4 to 6 hours after a magnesium-containing supplement [57,62].

Chronic treatment with loop diuretics, such as furosemide (Lasix) and bumetanide (Bumex), and thiazide diuretics, such as hydrochlorothiazide (Aquazide H) and ethacrynic acid (Edecrin), can increase the loss of magnesium in urine and lead to magnesium depletion [63]. In contrast, potassium-sparing diuretics, such as amiloride (Midamor) and spironolactone (Aldactone), reduce magnesium excretion [63].

Prescription proton pump inhibitor (PPI) drugs, such as esomeprazole magnesium (Nexium) and lansoprazole (Prevacid), can cause hypomagnesemia when taken for prolonged periods (typically more than a year) [64]. In the cases that FDA reviewed, magnesium supplements often raised the low serum magnesium levels caused by PPIs. However, in 25% of the cases, supplements did not raise magnesium levels and the patients had to discontinue the PPI. FDA advises health care professionals to consider measuring patients' serum magnesium levels prior to initiating long-term PPI treatment and to check magnesium levels in these patients periodically [64].

Where did MEDucated get this?

Magnesium — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Interactions with Medications
ODS revision
January 6, 2026
Retrieved
2026-08-10T22:07:04.128Z
Source fingerprint
0f84702092574ff8a3b3fe01ab3a977c6a76d37e18b758e3e94b6d3ca55c3d59
Cited reference numbers
57, 61, 62, 63, 64
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Vitamin D

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
13 identified
Human evidence
Human evidence identified
Randomized trials
Randomized trial identified
Reviews and meta-analyses
Systematic review or meta-analysis identified
Evidence recency
1984–2013
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Study type could not be determined10
  • Systematic review1
  • Randomized controlled trial2
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord 2001;25:1154-60. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  2. James WP, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes Relat Metab Disord 1997;21:S24-30. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  3. McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002;22:814-22. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  4. Robien K, Oppeneer SJ, Kelly JA, Hamilton-Reeves JM. Drug-vitamin D interactions: A systematic review of the literature. Nutr Clin Pract 2013;28:194-208. [PubMed abstract]

    Systematic review · Population basis: unknown · Directness: not assessed
  5. Schwartz JB. Effects of vitamin D supplementation in atorvastatin-treated patients: A new drug interaction with an unexpected consequence. Clin Pharmacol Ther 2009;85:198-203. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  6. Perez-Castrillon JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G, Duenas A. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol 2007;99:903-5. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  7. Aloia JF, Li-Ng M, Pollack S. Statins and vitamin D. Am J Cardiol 2007;100:1329. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  8. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961-8. [PubMed abstract]

    Randomized controlled trial · Population basis: human · Directness: not assessed
  9. de Sevaux RGL, Hoitsma AJ, Corstens FHM, Wetzels JFM. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 2002;13:1608-14. [PubMed abstract]

    Randomized controlled trial · Population basis: unknown · Directness: not assessed
  10. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  11. Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: Results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006. J Clin Endocrinol Metab 2011;96:3838-45. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  12. Drinka PJ, Nolten WE. Hazards of treating osteoporosis and hypertension concurrently with calcium, vitamin D, and distal diuretics. J Am Geriatr Soc 1984;32:405-7. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  13. Crowe M, Wollner L, Griffiths RA. Hypercalcaemia following vitamin D and thiazide therapy in the elderly. Practitioner 1984;228:312-3. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
Source safety wording remains visible

Vitamin D supplements may interact with medications, and some medications may affect vitamin D levels. These medications include orlistat, statins, steroids, and thiazide diuretics.

Vitamin D supplements may interact with several types of medications. A few examples are provided below. Individuals taking these and other medications on a regular basis should discuss their vitamin D intakes and status with their health care providers.

The weight-loss drug orlistat (Xenical and alli), together with a reduced-fat diet, can reduce the absorption of vitamin D from food and supplements, leading to lower 25(OH)D levels [167-170].

Statin medications reduce cholesterol synthesis. Because endogenous vitamin D is derived from cholesterol, statins may also reduce vitamin D synthesis [170]. In addition, high intakes of vitamin D, especially from supplements, might reduce the potency of atorvastatin (Lipitor), lovastatin (Altoprev and Mevacor), and simvastatin (FloLipid and Zocor), because these statins and vitamin D appear to compete for the same metabolizing enzyme [170-173].

Corticosteroid medications, such as prednisone (Deltasone, Rayos, and Sterapred), are often prescribed to reduce inflammation. These medications can reduce calcium absorption and impair vitamin D metabolism [174-176]. In the NHANES 2001–2006 survey, 25(OH)D deficiency (less than 25 nmol/L [10 ng/mL]) was more than twice as common among children and adults who reported oral steroid use (11%) than in nonusers (5%) [177].

Thiazide diuretics (e.g., Hygroton, Lozol, and Microzide) decrease urinary calcium excretion. The combination of these diuretics with vitamin D supplements (which increase intestinal calcium absorption) might lead to hypercalcemia, especially among older adults and individuals with compromised renal function or hyperparathyroidism [170,178,179].

Where did MEDucated get this?

Vitamin D — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Interactions with Medications
ODS revision
June 27, 2025
Retrieved
2026-08-10T22:07:04.753Z
Source fingerprint
825b1a553a4a177e2d87fc412b0b4b21daa72ca92f4334a0096bc0dfa7f70a3c
Cited reference numbers
167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Evidence topic

Supplement interaction evidence

Unavailable for both

Magnesium

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Vitamin D

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Evidence topic

Food and nutrient interactions

Unavailable for both

Magnesium

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Vitamin D

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Evidence topic

Typical forms

Available for both

Magnesium

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
8 identified
Human evidence
Human evidence identified
Randomized trials
Randomized trial identified
Reviews and meta-analyses
Systematic reviews or meta-analyses not identified in the frozen metadata
Evidence recency
1990–2012
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Study type could not be determined6
  • Pharmacokinetic study1
  • Randomized controlled trial1
Source-described limitations
  • ODS describes a small study base

    The absorption of magnesium from different kinds of magnesium supplements varies. Forms of magnesium that dissolve well in liquid are more completely absorbed in the gut than less soluble forms [2,12]. Small studies have found that magnesium in the aspartate, citrate, lactate, and chloride forms is absorbed more completely and is more bioavailable than magnesium oxide and magnesium sulfate [12-16]. One study found that very high doses of zinc from supplements (142 mg/day) can interfere with magnesium absorption and disrupt the magnesium balance in the body [17].

Classified references
  1. Rude RK. Magnesium. In: Coates PM, Betz JM, Blackman MR, Cragg GM, Levine M, Moss J, White JD, eds. Encyclopedia of Dietary Supplements. 2nd ed. New York, NY: Informa Healthcare; 2010:527-37.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  2. Rude RK. Magnesium. In: Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR, eds. Modern Nutrition in Health and Disease. 11th ed. Baltimore, Mass: Lippincott Williams & Wilkins; 2012:159-75.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  3. Ranade VV, Somberg JC. Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans. Am J Ther 2001;8:345-57. [PubMed abstract]

    Pharmacokinetic study · Population basis: human · Directness: not assessed
  4. Firoz M, Graber M. Bioavailability of US commercial magnesium preparations. Magnes Res 2001;14:257-62. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  5. Mühlbauer B, Schwenk M, Coram WM, Antonin KH, Etienne P, Bieck PR, Douglas FL. Magnesium-L-aspartate-HCl and magnesium-oxide: bioavailability in healthy volunteers. Eur J Clin Pharmacol 1991;40:437-8. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  6. Lindberg JS, Zobitz MM, Poindexter JR, Pak CY. Magnesium bioavailability from magnesium citrate and magnesium oxide. J Am Coll Nutr 1990;9:48-55. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  7. Walker AF, Marakis G, Christie S, Byng M. Mg citrate found more bioavailable than other Mg preparations in a randomized, double-blind study. Mag Res 2003;16:183-91. [PubMed abstract]

    Randomized controlled trial · Population basis: unknown · Directness: not assessed
  8. Spencer H, Norris C, Williams D. Inhibitory effects of zinc on magnesium balance and magnesium absorption in man. J Am Coll Nutr 1994;13:479-84. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
Read imported source wording for Magnesium

Supplements can contain a variety of different forms of magnesium, and the absorption of these forms varies. In general, forms of magnesium that dissolve well in liquid have higher absorption than other forms, and the aspartate, citrate, lactate, and chloride forms of magnesium tend to have higher bioavailability than magnesium oxide and magnesium sulfate.

Magnesium supplements are available in a variety of forms, including magnesium oxide, citrate, and chloride [2,3]. The Supplement Facts panel on a dietary supplement label declares the amount of elemental magnesium in the product, not the weight of the entire magnesium-containing compound.

The absorption of magnesium from different kinds of magnesium supplements varies. Forms of magnesium that dissolve well in liquid are more completely absorbed in the gut than less soluble forms [2,12]. Small studies have found that magnesium in the aspartate, citrate, lactate, and chloride forms is absorbed more completely and is more bioavailable than magnesium oxide and magnesium sulfate [12-16]. One study found that very high doses of zinc from supplements (142 mg/day) can interfere with magnesium absorption and disrupt the magnesium balance in the body [17].

Study doseSource-described amount
Where did MEDucated get this?

Magnesium — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Dietary supplements
ODS revision
January 6, 2026
Retrieved
2026-08-10T22:07:04.128Z
Source fingerprint
0f84702092574ff8a3b3fe01ab3a977c6a76d37e18b758e3e94b6d3ca55c3d59
Cited reference numbers
2, 3, 12, 13, 14, 15, 16, 17
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Vitamin D

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
10 identified
Human evidence
Human evidence identified
Randomized trials
Randomized trial identified
Reviews and meta-analyses
Systematic review or meta-analysis identified
Evidence recency
2007–2020
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Systematic review1
  • Study type could not be determined6
  • Meta-analysis1
  • Randomized controlled trial2
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Silva MC, Furlanetto TW. Intestinal absorption of vitamin D: A systematic review. Nutr Rev 2018;76:60-76. [PubMed abstract]

    Systematic review · Population basis: unknown · Directness: not assessed
  2. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  3. Hirsch AL. Industrial Aspects of Vitamin D. In: Feldman D, Pike JW, Adams JS, eds. Vitamin D. 3rd ed. Academic Press; 2011:73-93.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  4. National Institutes of Health. Dietary Supplement Label Database. 2020.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  5. Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: A systematic review and meta-analysis. Am J Clin Nutr 2012;95:1357-64. [PubMed abstract]

    Meta-analysis · Population basis: unknown · Directness: not assessed
  6. Lehmann U, Hirche F, Stangl GI, Hinz K, Westphal S, Dierkes J. Bioavailability of vitamin D2 and D3 in healthy volunteers, a randomised placebo-controlled trial. J Clin Endocrin Metab 2013;98:4339-45. [PubMed abstract]

    Randomized controlled trial · Population basis: human · Directness: not assessed
  7. Logan VF, Gray AR, Peddie MC, Harper MJ, Houghton LA. Long-term vitamin D3 supplementation is more effective than vitamin D2 in maintaining serum 25-hydroxyvitamin D status over the winter months. Br J Nutr 2013;109:1082-8. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  8. Tripkovic L, Wilson LR, Hart K, Johnsen S, de Lusignan S, Smith CP, et al. Daily supplementation with 15 µg vitamin D2 compared with vitamin D3 to increase wintertime 25-hydroxyvitamin D status in healthy South Asian and white European women: A 12-wk randomized, placebo-controlled food-fortification trial. Am J Clin Nutr 2017;106:481-90. [PubMed abstract]

    Randomized controlled trial · Population basis: human · Directness: not assessed
  9. Graeff-Armas LA, Bendik I, Kunz I, Schoop R, Hull S, Beck M. Supplemental 25-hydroxycholecalciferol is more effective than cholecalciferol in raising serum 25-hydroxyvitamin D concentrations in older adults. J Nutr 2020;150:73-81. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  10. Quesada-Gomez JM, Bouillon R. Is calcifediol better than cholecalciferol for vitamin D supplementation? Osteoporos Int 2018;29:1697-1711. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
Read imported source wording for Vitamin D

Vitamin D is present in dietary supplements as either vitamin D2 or vitamin D3. Both can raise the serum level of 25(OH)D. However, research shows that vitamin D3 increases serum 25(OH)D levels to a greater extent than vitamin D2 and can maintain those higher levels for longer periods of time.

Dietary supplements can contain vitamins D2 or D3. Vitamin D2 is manufactured using UV irradiation of ergosterol in yeast, and vitamin D3 is typically produced with irradiation of 7-dehydrocholesterol from lanolin obtained from the wool of sheep [13,31]. An animal-free version of vitamin D3 sourced from lichen is also available [32]. People who avoid all animal-sourced products can contact dietary supplement manufacturers to ask about their sourcing and processing techniques.

Both vitamins D2 and D3 raise serum 25(OH)D levels, and they seem to have equivalent ability to cure rickets [4]. In addition, most steps in the metabolism and actions of vitamins D2 and D3 are identical. However, most evidence indicates that vitamin D3 increases serum 25(OH)D levels to a greater extent and maintains these higher levels longer than vitamin D2, even though both forms are well absorbed in the gut [33-36].

Some studies have used dietary supplements containing the 25(OH)D3 form of vitamin D. Per equivalent microgram dose, 25(OH)D3 is three to five times as potent as vitamin D3 [37,38]. However, no 25(OH)D3 dietary supplements appear to be available to consumers on the U.S. market at this time [32].

Where did MEDucated get this?

Vitamin D — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Dietary supplements
ODS revision
June 27, 2025
Retrieved
2026-08-10T22:07:04.753Z
Source fingerprint
825b1a553a4a177e2d87fc412b0b4b21daa72ca92f4334a0096bc0dfa7f70a3c
Cited reference numbers
13, 31, 32, 4, 33, 34, 35, 36, 37, 38
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Evidence topic

Evidence-backed dosage information

Available for both

Magnesium

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
1 identified
Human evidence
Human evidence not identified in the frozen metadata
Randomized trials
Randomized trials not identified in the frozen metadata
Reviews and meta-analyses
Systematic reviews or meta-analyses not identified in the frozen metadata
Evidence recency
1997–1997
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Government reference1
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Institute of Medicine (IOM). Food and Nutrition Board. Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington, DC: National Academy Press, 1997.

    Government reference · Population basis: unknown · Directness: not assessed
Read imported source wording for Magnesium

The Food and Nutrition Board at the National Academies of Sciences, Engineering, and Medicine has established Recommended Dietary Allowances and Adequate Intakes for magnesium. These values range from 310 to 420 mg for adults and from 30 to 410 mg for infants, children, and adolescents, depending on age, sex, and life stage.

RDA reference intakeAI reference intakeSource intake rangeSource-described amount

Intake recommendations for magnesium and other nutrients are provided in the Dietary Reference Intakes (DRIs) developed by the Food and Nutrition Board (FNB) at the National Academies of Sciences, Engineering, and Medicine [1]. DRI is the general term for a set of reference values used to plan and assess nutrient intakes of healthy people. These values include the following:

  • Recommended Dietary Allowance (RDA): Average daily level of intake sufficient to meet the nutrient requirements of nearly all (97%–98%) healthy individuals; often used to plan nutritionally adequate diets for individuals
  • Adequate Intake (AI): Intake at this level is assumed to ensure nutritional adequacy; established when evidence is insufficient to develop an RDA
  • Estimated Average Requirement (EAR): Average daily level of intake estimated to meet the requirements of 50% of healthy individuals; usually used to assess the nutrient intakes of groups of people and to plan nutritionally adequate diets for them; can also be used to assess the nutrient intakes of individuals
  • Tolerable Upper Intake Level (UL): Maximum daily intake unlikely to cause adverse health effects
RDA reference intakeAI reference intakeUL reference intake

Table 1 lists the current RDAs for magnesium [1]. For infants from birth to 12 months, the FNB established AIs for magnesium that are equivalent to the mean intake of magnesium in healthy, breastfed infants, with added solid foods for ages 7 to 12 months.

Table 1: Recommended Dietary Allowances (RDAs) for Magnesium in Milligrams (mg) [1]
AgeMaleFemalePregnancyLactation
0–6 months30 mg*30 mg*
7–12 months75 mg*75 mg*
1–3 years80 mg80 mg
4–8 years130 mg130 mg
9–13 years240 mg240 mg
14–18 years410 mg360 mg400 mg360 mg
19–30 years400 mg310 mg350 mg310 mg
31–50 years420 mg320 mg360 mg320 mg
51+ years420 mg320 mg
RDA reference intakeSource-described amount

*Adequate Intake (AI)

AI reference intake
Where did MEDucated get this?

Magnesium — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Recommended Intakes
ODS revision
January 6, 2026
Retrieved
2026-08-10T22:07:04.128Z
Source fingerprint
0f84702092574ff8a3b3fe01ab3a977c6a76d37e18b758e3e94b6d3ca55c3d59
Cited reference numbers
1
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Vitamin D

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
6 identified
Human evidence
Human evidence not identified in the frozen metadata
Randomized trials
Randomized trials not identified in the frozen metadata
Reviews and meta-analyses
Systematic review or meta-analysis identified
Evidence recency
2010–2024
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Government reference1
  • Clinical guideline3
  • Systematic review1
  • Study type could not be determined1
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.

    Government reference · Population basis: unknown · Directness: not assessed
  2. Sempos CT, Binkley N. 25-hydroxyvitamin D assay standardisation and vitamin D guidelines paralysis. Public Health Nutrition 2020;23:1153-64. [PubMed abstract]

    Clinical guideline · Population basis: unknown · Directness: not assessed
  3. Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024 Jul 12;109(8):1907-1947. [PubMed abstract]

    Clinical guideline · Population basis: unknown · Directness: not assessed
  4. Shah VP, Nayfeh T, Alsawaf Y, Saadi S, Farah M, et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guidelines on Vitamin D. J Clin Endocrinol Metab. 2024 Jul 12;109(8):1961-1974. [PubMed abstract]

    Systematic review · Population basis: unknown · Directness: not assessed
  5. Bouillon R. Comparative analysis of nutritional guidelines for vitamin D. Nat Rev Endocrinol 2017;13:466-79. [PubMed abstract]

    Clinical guideline · Population basis: unknown · Directness: not assessed
  6. Scientific Advisory Committee on Nutrition. Vitamin D and Health. 2016.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
Read imported source wording for Vitamin D

The Food and Nutrition Board at the National Academies of Sciences, Engineering, and Medicine has established Recommended Dietary Allowances and Adequate Intakes for vitamin D. These values range from 15 to 20 mcg (600–800 IU) for adults and from 10 to 15 mcg (400–600 IU) for infants, children, and adolescents, depending on age.

RDA reference intakeAI reference intakeSource intake rangeSource-described amount

Intake recommendations for vitamin D and other nutrients are provided in the Dietary Reference Intakes (DRIs) developed by expert committees of NASEM [1]. DRI is the general term for a set of reference values used for planning and assessing nutrient intakes of healthy people. These values include the following:

  • Recommended Dietary Allowance (RDA): Average daily level of intake sufficient to meet the nutrient requirements of nearly all (97%–98%) healthy individuals; often used to plan nutritionally adequate diets for individuals
  • Adequate Intake (AI): Intake at this level is assumed to ensure nutritional adequacy; established when evidence is insufficient to develop an RDA
  • Estimated Average Requirement (EAR): Average daily level of intake estimated to meet the requirements of 50% of healthy individuals; usually used to assess the nutrient intakes of groups of people and to plan nutritionally adequate diets for them; can also be used to assess the nutrient intakes of individuals
  • Tolerable Upper Intake Level (UL): Maximum daily intake unlikely to cause adverse health effects
RDA reference intakeAI reference intakeUL reference intake

The FNB established RDAs for vitamin D to indicate daily intakes sufficient to maintain bone health and normal calcium metabolism in healthy people. RDAs for vitamin D are listed in both micrograms (mcg) and International Units (IU); 1 mcg vitamin D is equal to 40 IU (Table 2). Even though sunlight is a major source of vitamin D for some people, the FNB based the vitamin D RDAs on the assumption that people receive minimal sun exposure [1]. For infants from birth to 12 months, the FNB developed AIs based on the amount of vitamin D that maintains serum 25(OH)D levels above 20 ng/mL (50 nmol/L) and supports bone development.

Source-described amount
Table 2: Recommended Dietary Allowances (RDAs) for Vitamin D in Micrograms (mcg) and International Units (IU) [1]
AgeMaleFemalePregnancyLactation
0–6 months*10 mcg (400 IU)*10 mcg (400 IU)*
7–12 months*10 mcg (400 IU)*10 mcg (400 IU)*
1–3 years15 mcg (600 IU)15 mcg (600 IU)
4–8 years15 mcg (600 IU)15 mcg (600 IU)
9–13 years15 mcg (600 IU)15 mcg (600 IU)
14–18 years15 mcg (600 IU)15 mcg (600 IU)15 mcg (600 IU)15 mcg (600 IU)
19–50 years15 mcg (600 IU)15 mcg (600 IU)15 mcg (600 IU)15 mcg (600 IU)
51–70 years15 mcg (600 IU)15 mcg (600 IU)
>70 years20 mcg (800 IU)20 mcg (800 IU)
*Adequate Intake (AI)
RDA reference intakeAI reference intakeSource-described amount

Many other countries around the world and some professional societies have somewhat different guidelines for vitamin D intakes [15]. These differences are a result of an incomplete understanding of the biology and clinical implications of vitamin D, different purposes for the guidelines (e.g., for public health in a healthy population or for clinical practice), and/or the use in some guidelines of observational studies in addition to randomized clinical trials to establish recommendations [9,15]. For example, the United Kingdom Scientific Advisory Committee on Nutrition recommends intakes of 10 mcg (400 IU)/day for individuals age 4 years and older [16]. The Endocrine Society recommends routine vitamin D supplementation for children and teens age 1 to 18 years, pregnant women, adults with pre-diabetes, and adults age 75 years and older, but not for healthy adults age 19 to 74 [11,12]. The Endocrine Society does not recommend specific doses but notes that all individuals should adhere to the RDA.

RDA reference intakeSource-described amount
Where did MEDucated get this?

Vitamin D — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Recommended Intakes
ODS revision
June 27, 2025
Retrieved
2026-08-10T22:07:04.753Z
Source fingerprint
825b1a553a4a177e2d87fc412b0b4b21daa72ca92f4334a0096bc0dfa7f70a3c
Cited reference numbers
1, 9, 11, 12, 15, 16
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Evidence topic

Populations needing caution

Available for both

Magnesium

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
9 identified
Human evidence
Human evidence identified
Randomized trials
Randomized trials not identified in the frozen metadata
Reviews and meta-analyses
Systematic reviews or meta-analyses not identified in the frozen metadata
Evidence recency
1994–2012
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Government reference1
  • Study type could not be determined8
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Institute of Medicine (IOM). Food and Nutrition Board. Dietary Reference Intakes: Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington, DC: National Academy Press, 1997.

    Government reference · Population basis: unknown · Directness: not assessed
  2. Rude RK. Magnesium. In: Coates PM, Betz JM, Blackman MR, Cragg GM, Levine M, Moss J, White JD, eds. Encyclopedia of Dietary Supplements. 2nd ed. New York, NY: Informa Healthcare; 2010:527-37.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  3. Tums®. 2012.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  4. Chaudhary DP, Sharma R, Bansal DD. Implications of magnesium deficiency in type 2 diabetes: a review. Biol Trace Elem Res 2010;134:119–29. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  5. Tosiello L. Hypomagnesemia and diabetes mellitus. A review of clinical implications. Arch Intern Med 1996;156:1143-8. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  6. Rivlin RS. Magnesium deficiency and alcohol intake: mechanisms, clinical significance and possible relation to cancer development (a review). J Am Coll Nutr 1994;13:416–23. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  7. Ford ES, Mokdad AH. Dietary magnesium intake in a national sample of U.S. adults. J Nutr 2003;133:2879-82. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  8. Musso CG Magnesium metabolism in health and disease. Int Urol Nephrol 2009;41:357-62. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  9. Barbagallo M, Belvedere M, Dominguez LJ. Magnesium homeostasis and aging. Magnes Res 2009;22:235-46. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
Read imported source wording for Magnesium

Certain groups of people are more likely than others to have magnesium inadequacy. These include people with gastrointestinal diseases, type 2 diabetes, or alcohol dependence and older adults.

Magnesium inadequacy can occur when intakes fall below the RDA but are above the amount required to prevent overt deficiency. The following groups are more likely than others to be at risk of magnesium inadequacy because they typically consume insufficient amounts or they have medical conditions (or take medications) that reduce magnesium absorption from the gut or increase losses from the body.

RDA reference intake

The chronic diarrhea and fat malabsorption that occurs in people with Crohn's disease, gluten-sensitive enteropathy (celiac disease), and regional enteritis can lead to magnesium depletion over time [2]. Resection or bypass of the small intestine, especially the ileum, typically leads to malabsorption and magnesium loss [2].

Magnesium deficits and increased urinary magnesium excretion can occur in people with insulin resistance and/or type 2 diabetes [25,26]. The magnesium loss appears to be secondary to higher concentrations of glucose in the kidney that increase urine output [2].

Magnesium deficiency is common in people with chronic alcoholism [2]. In these individuals, poor dietary intake and nutritional status; gastrointestinal problems, including vomiting, diarrhea, and steatorrhea (fatty stools) resulting from pancreatitis; renal dysfunction with excess excretion of magnesium into the urine; phosphate depletion; vitamin D deficiency; acute alcoholic ketoacidosis; and hyperaldosteronism secondary to liver disease can all contribute to decreased magnesium status [2,27].

Older adults have lower dietary intakes of magnesium than younger adults [21,28]. In addition, magnesium absorption from the gut decreases and renal magnesium excretion increases with age [29]. Older adults are also more likely to have chronic diseases or take medications that alter magnesium status, which can increase their risk of magnesium depletion [1,30].

Where did MEDucated get this?

Magnesium — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Groups at Risk of Magnesium Inadequacy
ODS revision
January 6, 2026
Retrieved
2026-08-10T22:07:04.128Z
Source fingerprint
0f84702092574ff8a3b3fe01ab3a977c6a76d37e18b758e3e94b6d3ca55c3d59
Cited reference numbers
2, 25, 26, 27, 1, 21, 28, 29, 30
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Vitamin D

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
16 identified
Human evidence
Human evidence identified
Randomized trials
Randomized trials not identified in the frozen metadata
Reviews and meta-analyses
Systematic review or meta-analysis identified
Evidence recency
2001–2020
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Government reference1
  • Systematic review2
  • Study type could not be determined10
  • Clinical guideline2
  • Narrative review1
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.

    Government reference · Population basis: unknown · Directness: not assessed
  2. Silva MC, Furlanetto TW. Intestinal absorption of vitamin D: A systematic review. Nutr Rev 2018;76:60-76. [PubMed abstract]

    Systematic review · Population basis: unknown · Directness: not assessed
  3. Brown LL, Cohen B, Tabor D, Zappala G, Maruvada P, Coates PM. The vitamin D paradox in Black Americans: A systems-based approach to investigating clinical practice, research, and public health—expert panel meeting report. BMC Proceedings, 2018;12(Suppl 6):6. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  4. Picciano MF. Nutrient composition of human milk. Pediatr Clin North Am 2001;48:53-67. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  5. Wagner CL, Greer FR, American Academy of Pediatrics Section on Breastfeeding, American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008;122:1142-52. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  6. Dawodu A, Tsang RC. Maternal vitamin D status: Effect on milk vitamin D content and vitamin D status of breastfeeding infants. Adv Nutr 2012;3:353-61. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  7. Davis CD, Dwyer JT. The 'sunshine vitamin': benefits beyond bone? J Natl Cancer Inst 2007;99:1563-5. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  8. Simon AE, Ahrens KA. Adherence to vitamin D intake guidelines in the United States. Pediatrics 2020;145:e20193574. [PubMed abstract]

    Clinical guideline · Population basis: unknown · Directness: not assessed
  9. Chalcraft JR, Cardinal LM, Wechsler PJ, Hollis BW, Gerow KG, Alexander BM, et al. Vitamin D synthesis following a single bout of sun exposure in older and younger men and women. Nutrients 2020; 12, 2237; doi:10.3390/nu12082237. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  10. Sowah D, Fan X, Dennett L, Hagtvedt R, Straube S. Vitamin D levels and deficiency with different occupations: A systematic review. BMC Public Health 2017;17:519. [PubMed abstract]

    Systematic review · Population basis: unknown · Directness: not assessed
  11. Pappa HM, Bern E, Kamin D, Grand RJ. Vitamin D status in gastrointestinal and liver disease. Curr Opin Gastroenterol 2008;24:176-83. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  12. Drincic A, Fuller E, Heaney RP, Armas LAG. 25-hydroxyvitamin D response to graded vitamin D3 supplementation among obese adults. J Clin Endocrinol Metab 2013;98:4845-51. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  13. Ekwaru JP, Zwicker JD, Holick MF, Giovannucci E, Veugelers PJ. The importance of body weight for the dose response relationship of oral vitamin D supplementation and serum 25-hydroxyvitamin D in healthy volunteers. PLOS ONE 2014;9:e111265. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  14. Chakhtoura M, Rahme M, Fuleihan E-H. Vitamin D metabolism in bariatric surgery. Endocrinol Metab Clin North Am 2017;46:947-82. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  15. Peterson L, Zeng X, Caufield-Noll CP, Schweitzer MA, Magnuson TH, Steele KE. Vitamin D status and supplementation before and after bariatric surgery: A comprehensive literature review. Surg Obes Relat Dis 2016;12:693-702. [PubMed abstract]

    Narrative review · Population basis: unknown · Directness: not assessed
  16. Chakhtoura MT, Nakhoul N, Akl EA, Mantzoros CS, El Hajj Guleihan GA. Guidelines on vitamin D replacement in bariatric surgery? Identification and systematic appraisal. Metabolism 2016;65:586-97. [PubMed abstract]

    Clinical guideline · Population basis: unknown · Directness: not assessed
Read imported source wording for Vitamin D

Certain groups of people are more likely than others to have inadequate vitamin D status. These include breastfed infants, older adults, people with limited sun exposure, people with dark skin, people with conditions that limit fat absorption, and people with obesity or those who have undergone gastric bypass surgery.

Obtaining sufficient vitamin D from natural (nonfortified) food sources alone is difficult. For many people, consuming vitamin D-fortified foods and exposing themselves to some sunlight are essential for maintaining a healthy vitamin D status. However, some groups might need dietary supplements to meet their vitamin D requirements. The following groups are among those most likely to have inadequate vitamin D status.

Consumption of human milk alone does not ordinarily enable infants to meet vitamin D requirements, because it provides less than 0.6 to 2.0 mcg/L (25 to 78 IU/L) [1,56,57]. The vitamin D content of human milk is related to the mother’s vitamin D status; studies suggest that the breastmilk of mothers who take daily supplements containing at least 50 mcg (2,000 IU) vitamin D3 have higher levels of the nutrient [57,58].

Source intake rangeSource-described amount

Although UVB exposure can produce vitamin D in infants, the American Academy of Pediatrics (AAP) advises parents to keep infants younger than 6 months out of direct sunlight, dress them in protective clothing and hats, and apply sunscreen on small areas of exposed skin when sun exposure is unavoidable [59]. The AAP recommends 10 mcg (400 IU)/day vitamin D supplements for exclusively and partially breastfed infants starting shortly after birth and lasting until they are weaned and consume at least 1,000 mL/day vitamin D-fortified formula or whole milk [57]. The AAP also recommends 10 mcg (400 IU)/day supplemental vitamin D for all infants who are not breastfed and ingest less than 1,000 mL/day vitamin D-fortified formula or milk. An analysis of NHANES 2009–2016 data found that only 20.5% of breastfed infants and 31.1% of infants who were not breastfed ingested these recommended amounts of supplements [60].

Source-described amount

Older adults are at increased risk of developing vitamin D insufficiency, partly because the skin's ability to synthesize vitamin D declines with age [1,61]. In addition, older adults are likely to spend more time than younger people indoors, and they might have inadequate dietary intakes of the vitamin [1].

Homebound individuals; people who wear long robes, dresses, or head coverings for religious reasons; and people with occupations that limit sun exposure are among the groups that are unlikely to obtain adequate amounts of vitamin D from sunlight [62]. The use of sunscreen also limits vitamin D synthesis from sunlight. However, because the extent and frequency of sunscreen use are unknown, the role that sunscreen may play in reducing vitamin D synthesis is unclear [1].

Greater amounts of the pigment melanin in the epidermal layer of the skin result in darker skin and reduce the skin’s ability to produce vitamin D from sunlight [1]. Black Americans, for example, typically have lower serum 25(OH)D levels than White Americans. However, whether these lower levels in persons with dark skin have significant health consequences is not clear [14]. Those of African American ancestry, for example, have lower rates of bone fracture and osteoporosis than do Whites (see the section below on bone health and osteoporosis).

Because vitamin D is fat soluble, its absorption depends on the gut’s ability to absorb dietary fat [4]. Fat malabsorption is associated with medical conditions that include some forms of liver disease, cystic fibrosis, celiac disease, Crohn’s disease, and ulcerative colitis [1,63]. In addition to having an increased risk of vitamin D deficiency, people with these conditions might not eat certain foods, such as dairy products (many of which are fortified with vitamin D), or eat only small amounts of these foods. Individuals who have difficulty absorbing dietary fat might therefore require vitamin D supplementation [63].

Individuals with a body mass index (BMI) of 30 or more have lower serum 25(OH)D levels than individuals without obesity. Obesity does not affect the skin’s capacity to synthesize vitamin D. However, greater amounts of subcutaneous fat sequester more of the vitamin [1]. People with obesity might need greater intakes of vitamin D to achieve 25(OH)D levels similar to those of people with normal weight [1,64,65].

Individuals with obesity who have undergone gastric bypass surgery can also become vitamin D deficient. In this procedure, part of the upper small intestine, where vitamin D is absorbed, is bypassed, and vitamin D that is mobilized into the bloodstream from fat stores might not raise 25(OH)D to adequate levels over time [66,67]. Various expert groups—including the American Association of Metabolic and Bariatric Surgery, The Obesity Society, and the British Obesity and Metabolic Surgery Society—have developed guidelines on vitamin D screening, monitoring, and replacement before and after bariatric surgery [66,68]

Where did MEDucated get this?

Vitamin D — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Groups at Risk of Vitamin D Inadequacy
ODS revision
June 27, 2025
Retrieved
2026-08-10T22:07:04.753Z
Source fingerprint
825b1a553a4a177e2d87fc412b0b4b21daa72ca92f4334a0096bc0dfa7f70a3c
Cited reference numbers
1, 56, 57, 58, 59, 60, 61, 62, 14, 4, 63, 64, 65, 66, 67, 68
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Evidence topic

Pregnancy and lactation considerations

Unavailable for both

Magnesium

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Vitamin D

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Evidence topic

Laboratory and test considerations

Available for both

Magnesium

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
4 identified
Human evidence
Human evidence identified
Randomized trials
Randomized trials not identified in the frozen metadata
Reviews and meta-analyses
Systematic review or meta-analysis identified
Evidence recency
2005–2012
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Study type could not be determined3
  • Systematic review1
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Rude RK. Magnesium. In: Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR, eds. Modern Nutrition in Health and Disease. 11th ed. Baltimore, Mass: Lippincott Williams & Wilkins; 2012:159-75.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  2. Volpe SL. Magnesium. In: Erdman JW, Macdonald IA, Zeisel SH, eds. Present Knowledge in Nutrition. 10th ed. Ames, Iowa; John Wiley & Sons, 2012:459-74.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  3. Gibson, RS. Principles of Nutritional Assessment, 2nd ed. New York, NY: Oxford University Press, 2005.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  4. Witkowski M, Hubert J, Mazur A. Methods of assessment of magnesium status in humans: a systematic review. Magnesium Res 2011;24:163-80. [PubMed abstract]

    Systematic review · Population basis: human · Directness: not assessed
Read imported source wording for Magnesium

Because most of the magnesium in the body is found inside cells or in bone, it is difficult to assess magnesium status. Measuring serum magnesium concentration is the most commonly used method for assessment, but serum levels do not accurately reflect total body magnesium levels or concentrations in specific tissues. Comprehensively evaluating magnesium status may require the use of both laboratory tests and a clinical assessment.

Assessing magnesium status is difficult because most magnesium is inside cells or in bone [3]. The most commonly used and readily available method for assessing magnesium status is measuring serum magnesium concentration, even though serum levels have little correlation with total body magnesium levels or concentrations in specific tissues [6]. Other methods for assessing magnesium status include measuring magnesium concentrations in erythrocytes, saliva, and urine; measuring ionized magnesium concentrations in blood, plasma, or serum; and conducting a magnesium-loading (or tolerance) test. No single method is considered satisfactory [7]. Some experts [4] but not others [3] consider the tolerance test (in which urinary magnesium is measured after parenteral infusion of a dose of magnesium) to be the best method to assess magnesium status in adults. To comprehensively evaluate magnesium status, both laboratory tests and a clinical assessment might be required [6].

Where did MEDucated get this?

Magnesium — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Assessing magnesium status
ODS revision
January 6, 2026
Retrieved
2026-08-10T22:07:04.128Z
Source fingerprint
0f84702092574ff8a3b3fe01ab3a977c6a76d37e18b758e3e94b6d3ca55c3d59
Cited reference numbers
3, 4, 6, 7
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Vitamin D

Source-backed preview

Imported NIH ODS source content is available for this topic. MEDucated has preserved the source wording and has not converted it into personalized guidance.

Structural characterization

Evidence profile

No overall rating assigned
Evidence source
NIH ODS evidence synthesis
Linked references
13 identified
Human evidence
Human evidence identified
Randomized trials
Randomized trials not identified in the frozen metadata
Reviews and meta-analyses
Systematic review or meta-analysis identified
Evidence recency
2007–2024
Source-described consistency
Not characterized in these source blocks
MEDucated evidence rating
Not assigned

Reference counts describe frozen source associations; a larger count does not establish stronger evidence.

Inspect technical evidence details
Evidence types identified
  • Government reference1
  • Study type could not be determined9
  • Clinical guideline2
  • Systematic review1
Source-described limitations

No explicit limitation phrase was identified in these imported source blocks.

Classified references
  1. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.

    Government reference · Population basis: unknown · Directness: not assessed
  2. Norman AW, Henry HH. Vitamin D. In: Erdman JW, Macdonald IA, Zeisel SH, eds. Present Knowledge in Nutrition, 10th ed. Washington DC: Wiley-Blackwell, 2012.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  3. Jones G. Vitamin D. In: Ross AC, Caballero B, Cousins RJ, Tucker KL, Ziegler TR, eds. Modern Nutrition in Health and Disease, 11th ed. Philadelphia: Lippincott Williams & Wilkins, 2014.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  4. Sempos CT, Heijboer AC, Bikle DD, Bollerslev J, Bouillon R, Brannon PM, et al. Vitamin D assays and the definition of hypovitaminosis D. Results from the First International Conference on Controversies in Vitamin D. Br J Clin Pharmacol 2018;84:2194-207. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  5. LeFevre ML. Screening for vitamin deficiency in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2015;162:133-40. [PubMed abstract]

    Study type could not be determined · Population basis: human · Directness: not assessed
  6. Brooks SPJ, Sempos CT. The importance of 25-hydroxyvitamin D assay standardization and the Vitamin D Standardization Program. Journal of AOAC International 2017;100:1223-4.

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  7. Taylor CL, Sempos CT, Davis CD, Brannon PM. Vitamin D: moving forward to address emerging science. Nutrients 2017, 9, 1308; doi:10.3390/mu9121308. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  8. Sempos CT, Binkley N. 25-hydroxyvitamin D assay standardisation and vitamin D guidelines paralysis. Public Health Nutrition 2020;23:1153-64. [PubMed abstract]

    Clinical guideline · Population basis: unknown · Directness: not assessed
  9. Office of Dietary Supplements, National Institutes of Health. Vitamin D Standardization Program (VDSP).

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  10. Demay MB, Pittas AG, Bikle DD, Diab DL, Kiely ME, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024 Jul 12;109(8):1907-1947. [PubMed abstract]

    Clinical guideline · Population basis: unknown · Directness: not assessed
  11. Shah VP, Nayfeh T, Alsawaf Y, Saadi S, Farah M, et al. A Systematic Review Supporting the Endocrine Society Clinical Practice Guidelines on Vitamin D. J Clin Endocrinol Metab. 2024 Jul 12;109(8):1961-1974. [PubMed abstract]

    Systematic review · Population basis: unknown · Directness: not assessed
  12. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
  13. Brown LL, Cohen B, Tabor D, Zappala G, Maruvada P, Coates PM. The vitamin D paradox in Black Americans: A systems-based approach to investigating clinical practice, research, and public health—expert panel meeting report. BMC Proceedings, 2018;12(Suppl 6):6. [PubMed abstract]

    Study type could not be determined · Population basis: unknown · Directness: not assessed
Read imported source wording for Vitamin D

Serum concentration of 25(OH)D is the main indicator of vitamin D status. However, the serum concentrations of 25(OH)D that are associated with vitamin D deficiency have not been definitively identified. The Food and Nutrition Board at the National Academies of Sciences, Engineering, and Medicine states that levels of 50 nmol/L (20 ng/mL) or more are sufficient for most people, and that the risk of deficiency increases at serum concentrations of less than 30 nmol/L (12 ng/mL).

Serum concentration of 25(OH)D is currently the main indicator of vitamin D status. It reflects vitamin D produced endogenously and that obtained from foods and supplements [1]. In serum, 25(OH)D has a fairly long circulating half-life of 15 days [1]. Serum concentrations of 25(OH)D are reported in both nanomoles per liter (nmol/L) and nanograms per milliliter (ng/mL). One nmol/L is equal to 0.4 ng/mL, and 1 ng/mL is equal to 2.5 nmol/L.

Assessing vitamin D status by measuring serum 25(OH)D concentrations is complicated by the considerable variability of the available assays (the two most common ones involve antibodies or chromatography) used by laboratories that conduct the analyses [5,6]. As a result, a finding can be falsely low or falsely high, depending on the assay used and the laboratory. The international Vitamin D Standardization Program has developed procedures for standardizing the laboratory measurement of 25(OH)D to improve clinical and public health practice [5,7-10].

In contrast to 25(OH)D, circulating 1,25(OH)2D is generally not a good indicator of vitamin D status because it has a short half-life measured in hours, and serum levels are tightly regulated by parathyroid hormone, calcium, and phosphate [1]. Levels of 1,25(OH)2D do not typically decrease until vitamin D deficiency is severe [2].

Although 25(OH)D functions as a biomarker of exposure, the extent to which 25(OH)D levels also serve as a biomarker of effect on the body (i.e., relating to health status or outcomes) is not clear [1,3].

Researchers have not definitively identified serum concentrations of 25(OH)D associated with deficiency (e.g., rickets), adequacy for bone health, and overall health. After reviewing data on vitamin D needs, an expert committee of the Food and Nutrition Board (FNB) at the National Academies of Sciences, Engineering, and Medicine (NASEM) concluded that people are at risk of vitamin D deficiency at serum 25(OH)D concentrations less than 30 nmol/L (12 ng/mL; see Table 1 for definitions of deficiency and inadequacy) [1]. Some people are potentially at risk of inadequacy at 30 to 50 nmol/L (12–20 ng/mL). Levels of 50 nmol/L (20 ng/mL) or more are sufficient for most people. The FNB also noted that serum concentrations greater than 125 nmol/L (50 ng/mL) can be associated with adverse effects [1] (Table 1). The Endocrine Society has not identified 25(OH)D concentrations associated with vitamin D sufficiency, insufficiency, and deficiency and does not recommend routine testing of 25(OH)D concentrations in healthy individuals [11,12].

Table 1: Serum 25-Hydroxyvitamin D [25(OH)D] Concentrations and Health [1]
nmol/L*ng/mL*Health status
<30<12Associated with vitamin D deficiency, which can lead to rickets in infants and children and osteomalacia in adults
30 to <5012 to <20Generally considered inadequate for bone and overall health in healthy individuals
≥50≥20Generally considered adequate for bone and overall health in healthy individuals
>125>50Linked to potential adverse effects, particularly at >150 nmol/L (>60 ng/mL)
*Serum concentrations of 25(OH)D are reported in both nanomoles per liter (nmol/L) and nanograms per milliliter (ng/mL). One nmol/L = 0.4 ng/mL, and 1 ng/mL = 2.5 nmol/L.

Optimal serum concentrations of 25(OH)D for bone and general health have not been established because they are likely to vary by stage of life, by race and ethnicity, and with each physiological measure used [1,13,14]. In addition, although 25(OH)D levels rise in response to increased vitamin D intake, the relationship is nonlinear [1]. The amount of increase varies, for example, by baseline serum levels and duration of supplementation.

Where did MEDucated get this?

Vitamin D — Fact Sheet for Health Professionals

NIH Office of Dietary Supplements. Government health-professional reference material imported without MEDucated medical review.

Source section
Assessing vitamin D status
ODS revision
June 27, 2025
Retrieved
2026-08-10T22:07:04.753Z
Source fingerprint
825b1a553a4a177e2d87fc412b0b4b21daa72ca92f4334a0096bc0dfa7f70a3c
Cited reference numbers
1, 5, 6, 7, 8, 9, 10, 2, 3, 11, 12, 13, 14
Inspect the official NIH ODS source (opens in a new tab)

Source attribution does not imply NIH or ODS endorsement of MEDucated.

Evidence topic

Regulatory information

Unavailable for both

Magnesium

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Vitamin D

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Evidence topic

Evidence limitations

Unavailable for both

Magnesium

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.

Vitamin D

Evidence unavailable

No source-backed evidence is currently available for this topic in MEDucated.

The attached ODS revision does not provide an imported source section for this topic.